Solid-state NMR in drug design and discovery for membrane-embedded targets

Nature Reviews Drug Discovery

Volumn 4, Issue 7, 2005, Pages 555-568

  Watts, Anthony ^a,b  

^a UNIVERSITY OF OXFORD   (United Kingdom)

^b RUTHERFORD APPLETON LABORATORY   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

3 METHYL 5 (1 METHYL 2 PYRROLIDINYL)ISOXAZOLE; 8 BENZYLOXY 2 METHYLIMIDAZO[1,2 A]PYRIDINE 3 ACETONITRILE; AMOXICILLIN; ANTIBIOTIC AGENT; CLARITHROMYCIN; G PROTEIN COUPLED RECEPTOR; IMIDAZOPYRIDINE DERIVATIVE; LIGAND; MEMBRANE PROTEIN; NANOPARTICLE; NEW DRUG; NICOTINE; NICOTINE DERIVATIVE; OUABAIN; PROTON PUMP INHIBITOR; RETINAL; SULFANILAMIDE DERIVATIVE; SULFATHIAZOLE;

BINDING SITE; CALCULATION; CARBON NUCLEAR MAGNETIC RESONANCE; CLINICAL TRIAL; COMPLEX FORMATION; CONFORMATIONAL TRANSITION; DRUG CONFORMATION; DRUG DESIGN; DRUG INFORMATION; DRUG PROTEIN BINDING; DRUG RESEARCH; DRUG STRUCTURE; DRUG SYNTHESIS; DRUG TARGETING; HIGH THROUGHPUT SCREENING; HUMAN; LIGAND BINDING; MACROMOLECULE; MOLECULAR SIZE; NITROGEN NUCLEAR MAGNETIC RESONANCE; NONHUMAN; NUCLEAR MAGNETIC RESONANCE SPECTROSCOPY; OPEN READING FRAME; PHARMACODYNAMICS; PHOSPHORUS NUCLEAR MAGNETIC RESONANCE; PRIORITY JOURNAL; PROTEIN STRUCTURE; PROTON NUCLEAR MAGNETIC RESONANCE; REVIEW; SOLID STATE; STRUCTURE ACTIVITY RELATION; STRUCTURE ANALYSIS;

COMPUTATIONAL BIOLOGY; DRUG DELIVERY SYSTEMS; DRUG DESIGN; LIGANDS; MAGNETIC RESONANCE SPECTROSCOPY; MEMBRANE PROTEINS; MEMBRANES, ARTIFICIAL; PROTEIN CONFORMATION; PROTON PUMPS;

EID: 22144499552     PISSN: 14741776     EISSN: None     Source Type: Journal    
DOI: 10.1038/nrd1773     Document Type: Review

References (70)

1. Terstappen, G. C. & Reggiani, A. In silico research in drug discovery. Trends Pharmacol. Sci. 22, 23-26 (2001).
2. Drews, J. Drug discovery: a historical perspective. Science 287, 1960-1964 (2000).
3. + conduction and selectivity. Science 280, 69-77 (1998).
4. Denker, B. M., Smith, B. L., Kuhajda, F. P. & Agre, P. Identification, purification, and partial characterization of a novel Mr28,000 integral membrane protein from erythrocytes and renal tubes. J. Biol. Chem. 263, 15634-15642 (1988).
5. Tucker, J. & Grisshammer, R. Purification of a rat neurotensin receptor expressed in Escherichia coli. Biochem. J. 317, 891-899 (1996).
6. 2-adrenoreceptor coupled to the long splice variant of Gsa has properties of a constitutively active receptor. J. Biol. Chem. 273, 5109-5116 (1998).
7. 15N NMR evidence for a complex Schiff base counterion in the visual G-protein-coupled receptor rhodopsin. Biochemistry 38, 7195-7199 (1999).
8. 15N]-labeled membrane proteins in oriented lipid bilayers. J. Biomol. NMR 22, 225-247 (2002).
9. Riek, R., Pervushin, K. & Wüthrich, K. TROSY and CRINEPT: NMR with large molecular and supramolecular structures in solution. Trends Biochem. Sci. 25, 462-468 (2000).
10. Watts, A. et al. in Methods in Molecular Biology: Techniques in Protein NMR (ed. Downing, K.) (Humana, Totowa, New Jersey, 2004).
11. Roberts, G. C. K. Applications of NMR in drug discovery. Drug Discov. Today 5, 230-240 (2000).
12. Pellecchia, M., Sem, D. S. & Wüthrich, K. NMR in drug discovery. Nature Rev. Drug. Discov. 1, 211-219 (2002).
13. Shuker, S., Hajduk, P., Meadows, R. & Fesik, S. Discovering high-affinity ligands for proteins: SAR by NMR. Science 274, 1531-1534 (1996).
14. Watts, A. Direct studies of ligand-receptor interactions and ion channel blocking. Mol. Memb. Biol. 19, 267-275 (2002).
15. Watts, A. et al. Membrane protein structure determination by solid state NMR. Nat. Prod. Rep. 16, 419-423 (1999).
16. Watts, A. NMR of drugs and ligands bound to membrane receptors. Curr. Opin. Biotechnol. 10, 48-53 (1999).
17. Watts, A. Structural resolution of ligand-receptor interactions in functional, membrane-embedded receptors and proteins using novel, non-perturbing solid state NMR methods. Pharm. Pharm. Comm. 5, 7-13 (1999).
18. + symport protein in native membranes. Proc. Natl Acad. Sci. USA 91, 3877-3881 (1994).
19. Spooner, P. J. R., Veenhoff, L. M., Watts, A. & Poolman, B. Structural information on a membrane transport protein from nuclear magnetic resonance spectroscopy using sequence-selective nitroxide labeling. Biochemistry 38, 9634-9639 (1999)
20. Creuzet, F. et al. Determination of membrane-protein structure by rotational resonance NMR: bacteriorhodopsin. Science 251, 783-786 (1991).
21. Gröbner, G. et al. Observation of light-induced structural changes of retinal within rhodopsin. Nature 405, 810-813 (2000).
22. Ulrich, A. S., Wallat, I., Heyn, M. P. & Watts, A. Re-orientation of retinal in the M-photointermediate of bacteriorhodopsin. Nature Struct. Biol. 2, 190-192 (1995).
23. Carravetta, M. et al. Protein-induced bonding perturbation of the rhodopsin chromophore detected by double-quantum solid-state NMR. J. Am. Chem. Soc. 126, 3948-3953 (2004).
24. Blundell, T. L., Jhoti, H. & Abell, C. High-throughput crystallography for lead discovery in drug design. Nature Rev. Drug Discov. 1, 45-54 (2002).
25. Toyoshima, C. & Nomura, H. Structural changes in the calcium pump accompanying the dissociation of calcium. Nature 418, 605-611 (2002).
26. +-ATPase binding site determined by rotational echo double resonance NMR. J. Biol. Chem. 276, 43197-43204 (2001).
27. Middleton, D. A., Rankin, S., Esmann, M. & Watts, A. Structural insights into the binding of cardiac glycosides to the digitalis receptor revealed by solid-state NMR. Proc. Natl Acad. Sci. USA 97, 13602-13607 (2000).
28. +-ATPase - homology modelling of reversible inhibitor sites. J. Med. Chem. (in the press).
29. Miyazawa, A., Fujiyoshi, Y., Stowell, M. & Unwin, N. Nicotinic acetylcholine receptor at 4.6Å resolution: transverse tunnels in the channel wall. J. Mol. Biol. 288, 765-786 (1999).
30. Miyazawa, A., Fujiyoshi, Y. & Unwin, N. Structure and gating mechanism of the acetylcholine receptor pore. Nature 424, 949 (2003).
31. Fraenkel, Y., Gershoni, J. M. & Navon, G. NMR analysis reveals a positively charged hydrophobic domain as a common motif to bound acetylcholine and D-tubocurarine. Biochemistry 33, 644-650 (1994).
32. +(CD3)3-bromoacetylcholine bound to its binding site on the nicotinic acetylcholine receptor. Proc. Natl Acad. Sci. USA 98, 2346-2351 (2001).
33. Williamson, P. T. F., Gröbner, G., Spooner, P. J. R., Miller, K. W. & Watts, A. Probing the agonist binding pocket on the nicotinic acetylcholine receptor: a high resolution solid state NMR approach. Biochemistry 37, 10854-10859 (1998).
34. Gallivan, J. P. & Dougherty, D. A. Cation-π interactions in structural biology. Proc. Natl Acad. Sci. USA 96, 9459-9464 (1999).
35. Sabbagh, M., Lukas, R., Sparks, D. & Reid, R. The nicotinic acetylcholine receptor, smoking, and Alzheimer's disease. J. Alzheimers Dis. 4, 317-325 (2002).
36. Shytle, R. et al. Cholinergic modulation of microglial activation by α7 nicotinic receptors. J. Neurochem. 89, 337-343 (2004).
37. Terry, A. J. & Buccafusco, J. The cholinergic hypothesis of age and Alzheimer's disease-related cognitive deficits: recent challenges and their implications for novel drug development. J. Pharmacol. Exo. Ther. 306, 821-827 (2003).
38. Romano, J. A possible explanation for nicotine's neuroprotective effect. Neurol. Rev. 12, 4 (2004).
39. Arehart-Treichel, J. A. Role for nicotine in Alzheimer's, other disorders. Psych. News (17 March 2000).
40. Wilens, T. E. et al. A pilot controlled clinical trial of ABT-418, a cholinergic agonist, in the treatment of adults with attention deficit hyperactivity disorder. Am. J. Psych. 156, 1931-1937 (1999).
41. Kelly, C. & McCreadie, R. Smoking habits, current symptoms, and premorbid characteristics of schizophrenic patients in Nithsdale, Scotland. Am. J. Psych. 156, 1751-1757 (1999).
42. Pebay-Peyroula, E., Rummel, G., Rosenbusch, J. P. & Landau, E. M. X-ray structure of bacteriorhodopsin at 2.5 angstroms from microcrystals grown in lipidic cubic phases. Science 277, 1676-1681 (1997).
43. Luecke, H., Schubert, B., Richter, H. T., Cartailler, J. P. & Lanyi, J. K. Structure of bacteriorhodopsin at 1.55Å resolution. J. Mol. Biol. 291, 899-911 (1999).
44. Gröbner, G. et al. Macroscopic orientation of natural and model membranes for structural studies. Anal. Biochem. 254, 132-136 (1997).
45. Kamihira, M. et al. Structural and orientational constraints of bacteriorhodopsin in purple membranes determined by oriented-sample solid-state NMR spectroscopy. J. Struct. Biol. 149, 7-16 (2005).
46. Merlitz, H., Burghardt, B. & Wenzel, W. Stochastic tunneling method for high-throughput database screening. Nanotechnology 1, 44-47 (2003).
47. Fraser, D. M., Van Gorkom, L. C. M. & Watts, A. Partitioning behaviour of 1- hexanol into lipid membranes as studied by deuterium NMR spectroscopy. Biochim. Biophys. Acta 1069, 53-60 (1991).
48. 2H NMR approach. J. Pharm. Sci. 93, 507-514 (2004).
49. Hu, J. G. et al. Early and late M intermediates in the bacteriorhodopsin photocycle: a solid-state NMR study. Biochemistry 37, 8088-8096 (1998).
50. 15N labeled membrane protein: distances between the Schiff Base and aspartic acids in the active site of bacteriorhodopsin. J. Am. Chem. Soc. 123, 12929-12930 (2001).
51. Lemaitre, V. et al. New insights onto the bonding arrangements of L- and D-glutamates from solid state 170 NMR. Chem. Phys. Lett. 371, 91-97 (2003).
52. Lansing, J. C., Hu, J. G., Belenky, M., Griffin, R. G. & Herzfeld, J. Solid-state NMR investigation of the buried X-proline peptide bonds of bacteriorhodopsin. Biochemistry 42, 3586-3593 (2003).
53. 15N-labeled membrane protein: distances between the Schiff Base and aspartic acids in the active site of Bacteriorhodopsin. J. Am. Chem. Soc. 123, 12929-12930 (2001).
54. Castellani, F. et al. Structure of a protein determined by solid-state magic angle-spinning NMR spectroscopy. Nature 420, 98-102 (2003).
55. Palczewski, K. et al. Crystal structure of rhodopsin: a G protein-coupled receptor. Science 277, 687-690 (2000).
56. Opella, S. J. NMR and membrane proteins. Nature Struct. Biol. 4 (Suppl.), 845-848 (1997).
57. Griffin, R. G. Dipolar recoupling in MAS spectra of biological solids. Nature Struct. Biol. 5, 508-512 (1998).
58. Tycko, R. Biomolecular solid state NMR: advances in structural methodology and applications to peptide and protein fibrils. Annu. Rev. Phys. Chem. 52, 575-606 (2001).
59. Thompson, L. K. Solid state NMR studies of the structure and mechanisms of proteins. Curr. Opin. Struct. Biol. 12, 661-669 (2002).
60. Zech, S. G., Olejniczak, E., Hajduk, P., Mack, J. & McDermott, A. E. Characterization of protein-ligand interactions by high-resolution solid-state NMR spectroscopy. J. Am. Chem. Soc. 126, 13948-13953 (2004).
61. Bernstein, J. Polymorphism in Molecular Crystals (Oxford Univ. Press, Oxford, 2002).
62. Lemaitre, V., Smith, M. E. & Watts, A. A review of oxygen-17 solid state NMR of organic materials: towards biological applications. Solid State Nuc. Mag. Res. 25, 215-235 (2004).
63. Levitt, M. H., Raleigh, D. P., Creuzet, F. & Griffin, R. G. Theory and simulations of homonuclear spin pair systems in rotating solids. J. Chem. Phys. 92, 6347-6364 (1990).
64. Guillon, T. Introduction to rotational-echo double resonance NMR. Conc. Mag. Res. 10, 277-289 (1998).
65. Caira, M. R. in Design of Organic Solids 163-208 Springer-Verlag, Heidelberg, 1998).
66. Threlfall, T. L. Analysis of organic polymorphs. A review. Analyst 120, 2435-2460 (1995).
67. Yu, L., Reutzel, S. M. & Stephenson, G. A. Physical characterization of polymorphic drugs: an integrated characterization strategy. Pharm. Sci. Technol. Today 1, 118-127 (1999).
68. 15N solid state NMR, together with shielding calculations. Magn. Reson. Chem. 42, 313-320 (2004).
69. Apperley, D. C. et al. Sulfathiazole polymorphism studied by magic-angle spinning NMR. J. Pharm. Sci. 88, 1275-1280 (1999).
70. Midleton, D. A. et al. The conformation of an inhibitor bound to gastric proton pump. FEBS Letts. 410, 269-274 (1997).